vida: extract claims from 2026-05-03-lancet-semalco-semaglutide-aud-rct-results

- Source: inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions.md

@@ -31,3 +31,10 @@ First Phase 2 RCT showing semaglutide produces large-range effect sizes (Cohen d
 **Source:** Science Media Centre expert reactions, April 30, 2026
 
 Expert consensus on SEMALCO trial confirms that behavioral and biological interventions are inseparable for AUD treatment. All participants received CBT alongside semaglutide, and experts emphasized this makes it impossible to determine whether the drug works without behavioral support. The trial design itself assumes the dichotomy is false - no arm tested semaglutide alone, suggesting clinical investigators believe the biological intervention requires behavioral scaffolding to produce durable outcomes.
+
+
+## Supporting Evidence
+
+**Source:** SEMALCO trial, The Lancet 2026
+
+Semaglutide's superior AUD efficacy (NNT 4.3 vs 7+ for approved medications) combined with simultaneous cigarette reduction in concurrent users demonstrates that reward dysregulation conditions respond to biological intervention targeting mesolimbic dopamine pathways, not just behavioral therapy. Both SEMALCO arms received CBT, yet semaglutide arm showed 50% higher absolute reduction in heavy drinking days.

domains/health/cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions.md

@@ -10,12 +10,16 @@ agent: vida
 scope: causal
 sourcer: Breedvelt, Warren, Segal, Kuyken, Bockting — JAMA Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]"]
-related:
-- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
-reweave_edges:
-- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication|related|2026-04-12
+related: ["Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication", "cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
+reweave_edges: ["Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication|related|2026-04-12"]
 ---
 
 # Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
 
-Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, and critically, CBT and continued medication did not differ significantly from each other in relapse prevention. Antidepressant discontinuation produced 34.81% relapse at 6 months and 45.12% at 12 months, while CBT after/during tapering provided protection comparable to continued medication. The mechanism is skill acquisition: CBT teaches cognitive and behavioral strategies that patients retain after therapy ends, providing 'enduring effects that extend beyond the end of treatment.' This finding has been replicated across multiple meta-analyses including the December 2025 Lancet Psychiatry NMA covering 76 RCTs and 17,000+ adults. No clinical moderators were associated with differential risk—the CBT advantage holds across patient subgroups. This represents a fundamental difference from metabolic interventions like GLP-1 agonists, where there is no 'skill analog' that allows patients to maintain benefits after drug cessation—you cannot do 'GLP-1 skills training' that substitutes for continuous pharmacotherapy. The contrast reveals that behavioral/cognitive interventions can escape the continuous-treatment model through durable skill acquisition, while pharmacological interventions require ongoing delivery to maintain effect.
+Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, and critically, CBT and continued medication did not differ significantly from each other in relapse prevention. Antidepressant discontinuation produced 34.81% relapse at 6 months and 45.12% at 12 months, while CBT after/during tapering provided protection comparable to continued medication. The mechanism is skill acquisition: CBT teaches cognitive and behavioral strategies that patients retain after therapy ends, providing 'enduring effects that extend beyond the end of treatment.' This finding has been replicated across multiple meta-analyses including the December 2025 Lancet Psychiatry NMA covering 76 RCTs and 17,000+ adults. No clinical moderators were associated with differential risk—the CBT advantage holds across patient subgroups. This represents a fundamental difference from metabolic interventions like GLP-1 agonists, where there is no 'skill analog' that allows patients to maintain benefits after drug cessation—you cannot do 'GLP-1 skills training' that substitutes for continuous pharmacotherapy. The contrast reveals that behavioral/cognitive interventions can escape the continuous-treatment model through durable skill acquisition, while pharmacological interventions require ongoing delivery to maintain effect.
+
+## Extending Evidence
+
+**Source:** SEMALCO trial, The Lancet 2026
+
+SEMALCO trial design (both arms received CBT) prevents isolation of semaglutide monotherapy efficacy for AUD. The 26-week trial duration provides no post-discontinuation durability data, leaving open whether GLP-1 AUD treatment requires continuous administration like metabolic indications or whether CBT co-intervention enables durable benefit after cessation.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -95,3 +95,10 @@ Swedish national cohort (n=95,490) shows semaglutide reduces depression worsenin
 **Source:** eClinicalMedicine meta-analysis, 2025
 
 Meta-analysis of 5.26M patients across 14 studies shows 28-36% reduction in AUD-related outcomes with neuroimaging confirmation of attenuated alcohol cue reactivity and dopaminergic signaling. Objective biomarkers (PEth, γ-GT) validated behavioral findings. Three independent meta-analyses in 2025-2026 converged on similar effect sizes, indicating robust replication.
+
+
+## Supporting Evidence
+
+**Source:** SEMALCO trial, The Lancet 2026
+
+SEMALCO Phase 2 RCT (N=108, 26 weeks) showed semaglutide 2.4mg reduced heavy drinking days 41% vs 26% placebo (p=0.0015) with NNT=4.3, outperforming all approved AUD medications (NNT≥7). Blood-alcohol biomarkers objectively confirmed self-report. Secondary finding: greater cigarette reduction in concurrent users suggests GLP-1 acts across reward circuits simultaneously, supporting mesolimbic dopamine mechanism rather than AUD-specific pathway.

domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "Phase 2 RCT shows semaglutide 2.4mg reduces heavy drinking days 41% vs 26% placebo with NNT 4.3, outperforming all FDA-approved AUD medications"
+confidence: likely
+source: SEMALCO trial, The Lancet 2026, Mental Health Center Copenhagen
+created: 2026-05-03
+title: Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health
+agent: vida
+sourced_from: health/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md
+scope: causal
+sourcer: The Lancet (SEMALCO trial team)
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+challenges: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial"]
+---
+
+# Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health
+
+The SEMALCO trial (N=108, 26 weeks, double-blind RCT) demonstrated semaglutide 2.4mg weekly reduced heavy drinking days by 41.1% from baseline (95% CI −48.7 to −33.5) versus 26.4% for placebo (−34.1 to −18.6), yielding a treatment difference of −13.7 percentage points (p=0.0015). This translates to NNT=4.3, compared to NNT≥7 for all currently FDA-approved AUD medications (naltrexone, acamprosate, disulfiram). Blood-alcohol biomarkers objectively confirmed self-reported findings, strengthening validity. Secondary outcomes showed significant reductions in drinks per drinking day and weekly alcohol craving, plus greater cigarette reduction in concurrent users, suggesting GLP-1 acts across reward circuits simultaneously rather than AUD-specifically. Critical scope qualifications: (1) population limited to AUD with comorbid obesity (BMI≥30), (2) both arms received CBT so semaglutide monotherapy efficacy unknown, (3) 26-week duration provides no long-term durability data, (4) single-center design limits generalizability. This is the largest RCT of semaglutide for AUD to date and represents the most clinically significant AUD pharmacotherapy finding in over a decade. Phase 3 trials underway (NCT05520775, NCT07218354) but timelines not publicly disclosed. FDA has not approved GLP-1 drugs for addiction treatment as of February 2026.

entities/health/semalco-trial.md

@@ -0,0 +1,59 @@
+# SEMALCO Trial
+
+**Full name:** Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity
+
+**Institution:** Mental Health Center Copenhagen, Psychiatric Centre Copenhagen
+
+**Trial type:** Phase 2, randomized, double-blind, placebo-controlled
+
+**Status:** Published April 2026 in The Lancet
+
+## Design
+
+- **Population:** N=108 treatment-seeking patients with moderate-to-severe AUD + comorbid obesity (BMI ≥30 kg/m²)
+- **Duration:** 26 weeks
+- **Intervention:** Semaglutide 2.4mg subcutaneous weekly vs. placebo (saline), randomized 1:1
+- **Co-intervention:** Both arms received standard cognitive behavioral therapy (CBT)
+- **Setting:** Single-center (Mental Health Center Copenhagen)
+
+## Primary Outcome
+
+**Heavy drinking days reduction:**
+- Semaglutide: 41.1% reduction from baseline (95% CI −48.7 to −33.5)
+- Placebo: 26.4% reduction (−34.1 to −18.6)
+- Treatment difference: −13.7 percentage points (−22.0 to −5.4; p=0.0015)
+- NNT = 4.3 (vs. NNT ≥7 for all FDA-approved AUD medications)
+
+## Secondary Outcomes
+
+- **No significant effect on:** Average drinks/day, total drinking days
+- **Significant reductions in:** Drinks per drinking day, weekly alcohol craving
+- **Objective validation:** Blood-alcohol biomarkers confirmed self-reported findings
+- **Cross-substance effect:** Greater cigarette reduction in subgroup with concurrent tobacco use
+
+## Safety
+
+GI side effects (nausea, loss of appetite, constipation, vomiting) occurred significantly more frequently with semaglutide but were generally mild and transient.
+
+## Significance
+
+- Largest RCT of semaglutide for AUD to date (previous: 48-person, 9-week, non-treatment-seeking trial)
+- Superior efficacy to all currently approved AUD medications
+- First Phase 2 evidence for GLP-1 receptor agonists in AUD with comorbid obesity
+
+## Limitations
+
+- Single-center design reduces generalizability
+- AUD+obesity comorbidity requirement — cannot extrapolate to AUD without obesity
+- Both arms received CBT — unclear if semaglutide monotherapy would work
+- 26 weeks — no long-term durability data post-discontinuation
+
+## Related Trials
+
+- NCT05520775: "Semaglutide for Alcohol Use Disorder" (separate trial)
+- NCT07218354: Phase 3 design, details limited
+
+## Timeline
+
+- **2026-04-01** — Published in The Lancet
+- **2026-04** — Covered by NIH press release, MedicalXpress, PsychNews, multiple outlets

inbox/archive/health/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-03
 priority: high
 tags: [GLP-1, semaglutide, alcohol-use-disorder, AUD, behavioral-health, addiction-medicine, RCT, clinical-trial]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content